Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver damage
Biotech
Vir keeps pressure on Gilead with midphase hepatitis D data
Vir's hepatitis D therapy has shown efficacy in a phase 2 test, suggesting the cocktail may pose a threat to Gilead’s attempt in the market.
Nick Paul Taylor
Jun 5, 2024 8:52am
Ipsen ends 2021 deal spree with $543M Genfit tie-up
Dec 17, 2021 10:25am
Bristol Myers becomes latest victim of unforgiving NASH
Nov 18, 2021 10:40am
Enyo Pharma notches a mid-stage trial win in tricky NASH
Jul 28, 2021 10:18am
Inipharm raises $35M to combat liver diseases
Nov 11, 2020 8:00am
Vir and Alnylam post hep B data peek
Aug 28, 2020 10:45am
